# US 2012/0232092 A1 · Heterocyclic sulfonamides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0232092 A1
- Document ID: US20120232092A1
- Status: Published application
- Kind: A1
- Application number: 13/474,824
- Filed: 2012-05-18
- Published: 2012-09-13
- Earliest claimed: 2003-03-27
- Assignees: Cytokinetics, Inc.
- Inventors: Bradley Paul Morgan; Fady Malik; Erica Anne Kraynack; Alexander Ramon Muci; Xiangping Qian; David J. Morgans, JR.
- Web page: https://patentgrep.com/patent/US20120232092A1

## CPC

- C07D 295/26: Sulfur atoms
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C07D 207/14: Nitrogen atoms not forming part of a nitro radical
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 233/88: Nitrogen atoms, e.g. allantoin
- C07D 257/06: with nitrogen atoms directly attached to the ring carbon atom
- C07D 261/14: Nitrogen atoms
- C07D 263/48: Nitrogen atoms not forming part of a nitro radical
- C07D 277/46: by carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D 285/135: Nitrogen atoms
- C07D 295/18: by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

## Claims

### Claim at position 1

1-14. (canceled)

### Claim 15

A compound of the following formula:
wherein:
R1, R2 and the nitrogen to which they are attached form a morphlin-4-yl ring optionally substituted with one, two, or three groups selected from alkyl, halogen, hydroxy, alkoxy, alkylenedioxy, carboxy, acyloxy, alkoxycarbonyl, alkoxycarbonylamino, alkylcarbonylamino, aminocarbonyl, aminocarbonylamino, cyano, acyl, oxo, nitro, amino, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, amidino, phenyl, benzyl, heteroaryl, heterocyclyl, aryloxy, aralkoxy, heteroaryloxy, and heteroaralkoxy, wherein the amino(s) in the aminocarbonyl, amino, or aminosulfonyl is optionally substituted with alkyl;
R3 is an aryl or heteroaryl group, which is optionally substituted with a halogen, lower alkoxy, aryl or heteroaryl group;
R4 is halogen;
R5 is hydrogen, halogen, hydroxy, or lower alkyl;
R6 and R7 are independently selected from hydrogen, halogen, hydroxy, and lower alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein R3 is a phenyl, isoxazolyl, oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, tetrazol-5-yl, thiazolyl, thiadiazolyl or imidazolyl group, which is optionally substituted with a halogen, lower alkoxy, aryl or heteroaryl group.

### Claim 17 (depends on 15)

The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein R3 is an [1,3,4]thiadiazol-2-yl group which is optionally substituted with a phenyl group.

### Claim 18 (depends on 15)

The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein R3 is 5-phenyl-[1,3,4]thiadiazol-2-yl.

### Claim 19 (depends on 18)

The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein
R4 is chloro; and
R5, R6 and R7 are hydrogen.

### Claim 20 (depends on 15)

The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein R3 is a 1H-imidazol-2-yl group.

### Claim 21 (depends on 20)

The compound of claim 20, or a pharmaceutically acceptable salt thereof, wherein
R4 is chloro; and
R5, R6 and R7 are hydrogen.

### Claim 22 (depends on 15)

The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein R3 is thiazol-2-yl.

### Claim 23 (depends on 22)

The compound of claim 22, or a pharmaceutically acceptable salt thereof, wherein
R4 is chloro; and
R5, R6 and R7 are hydrogen.

### Claim 24 (depends on 15)

The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein
R4 is chloro; and
R5, R6 and R7 are hydrogen.

### Claim 25 (depends on 15)

The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein R1, R2 and the nitrogen to which they are attached form an unsubstituted morphlin-4-yl ring.

### Claim 26 (depends on 15)

A pharmaceutical formulation comprising a pharmaceutically accepted excipient and a therapeutically effective amount of a compound of claim 15, or a pharmaceutically acceptable salt thereof.
